{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:17:37Z","timestamp":1780571857941,"version":"3.54.1"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Clinical trial data have demonstrated that direct oral anticoagulants (DOACs) are both noninferior to and safer than conventional therapy for the treatment of venous thromboembolism (VTE). This study aimed to compare the effectiveness and safety of DOACs versus warfarin using Nordic population-based registries.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    This observational cohort study used Swedish, Norwegian and Finnish national administrative data from 2012 to 2018. We identified treatment-naive adult patients with noncancer-related VTE treated with either a DOAC (apixaban or rivaroxaban) or warfarin. We employed inverse probability of treatment weighting for each DOAC-warfarin comparison and assessed the risks of bleeding (overall and by site: gastrointestinal bleeding [GI], intracranial bleeding [ICH], or other bleeding) and recurrent VTE within 6 months after treatment initiation. Cox proportional hazards models estimated the adjusted hazard ratios of each end point. Country estimates were combined using meta-analyses.\n                    <jats:bold>Results:<\/jats:bold>\n                    After inverse probability of treatment weighting, 22,450 warfarin, 14,542 apixaban and 23,002 rivaroxaban patients were included. At 6 months, for apixaban versus warfarin, the risk of bleeding was lower overall (hazard ratio: 0.51 [95% CI: 0.43, 0.61]) and by site (GI: 0.65 [0.45, 0.93]; ICH: 0.58 [0.34, 0.97]; other: 0.45 [0.34, 0.58]). For recurrent VTE the risk was similar for apixaban versus warfarin (0.85 [0.71, 1.02]). For rivaroxaban versus warfarin the risk of bleeding was lower for overall and other bleeding (0.86 [0.75, 0.99]; 0.81 [0.69, 0.95], respectively), but similar for GI and ICH bleeding (1.06 [0.84, 1.34]; 0.68 [0.47, 1.00], respectively). For recurrent VTE the risk was lower for rivaroxaban versus warfarin (0.74 [0.63, 0.87]).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    DOACs showed improved safety and at least similar effectiveness compared with warfarin, which is in line with clinical trial estimates.\n                  <\/jats:p>","DOI":"10.57264\/cer-2024-0207","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:20:56Z","timestamp":1758795656000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative safety and effectiveness of direct oral anticoagulants and warfarin in patients with venous thromboembolism in Finland, Norway and Sweden"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-6165","authenticated-orcid":false,"given":"Waleed","family":"Ghanima","sequence":"first","affiliation":[{"name":"Internal Medicine Clinic &amp; Department of Research, \u00d8stfold Hospital, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Pohjant\u00e4hti","sequence":"additional","affiliation":[{"name":"Tampere University Hospital, Heart Center, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Lambrelli","sequence":"additional","affiliation":[{"name":"Evidera Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Nordstrom","sequence":"additional","affiliation":[{"name":"Evidera Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Booth","sequence":"additional","affiliation":[{"name":"Evidera Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-1863","authenticated-orcid":false,"given":"Sophie","family":"Graham","sequence":"additional","affiliation":[{"name":"Evidera Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6278-4969","authenticated-orcid":false,"given":"Ruth","family":"Mokgokong","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Walton Oaks, Surrey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-9388","authenticated-orcid":false,"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Walton Oaks, Surrey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Chaves","sequence":"additional","affiliation":[{"name":"Pfizer SLU., Madrid, Spain,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-6863","authenticated-orcid":false,"given":"Feng","family":"Dai","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Subash","sequence":"additional","affiliation":[{"name":"Evidera Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0865-0000","authenticated-orcid":false,"given":"Anders","family":"Gotts\u00e4ter","sequence":"additional","affiliation":[{"name":"Lund University, Department of Clinical Sciences in Malm\u00f6, Malm\u00f6, Sweden"},{"name":"Department of Medicine, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"11","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden","volume":"34","author":"Raskob GE","year":"2014","unstructured":"Raskob GE, Angchaisuksiri P, Blanco AN Thrombosis: a major contributor to global disease burden. Arterioscler. Thromb. Vasc. Biol. 34(11), 2363\u20132371 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"e_1_3_7_4_2","article-title":"Deep venous thrombosis risk factors","author":"McLendon K","year":"2023","unstructured":"McLendon K, Goyal A, Attia M. Deep venous thrombosis risk factors. StatPearls (2023). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470215\/","journal-title":"StatPearls"},{"issue":"1","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12872-017-0587-1","article-title":"Incidence of acute pulmonary embolism, related comorbidities and survival; analysis of a Swedish national cohort","volume":"17","author":"Andersson T","year":"2017","unstructured":"Andersson T, Soderberg S. Incidence of acute pulmonary embolism, related comorbidities and survival; analysis of a Swedish national cohort. BMC Cardiovasc. Disord. 17(1), 155 (2017).","journal-title":"BMC Cardiovasc. Disord."},{"key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.thromres.2020.07.011","article-title":"Incidence and prevalence of venous thromboembolism in Norway 2010\u20132017","volume":"195","author":"Ghanima W","year":"2020","unstructured":"Ghanima W, Brodin E, Schultze A Incidence and prevalence of venous thromboembolism in Norway 2010\u20132017. Thromb. Res. 195, 165\u2013168 (2020).","journal-title":"Thromb. Res."},{"issue":"9","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe AM","year":"2016","unstructured":"Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ. Res. 118(9), 1340\u20131347 (2016).","journal-title":"Circ. Res."},{"issue":"4","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","article-title":"Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in germany","volume":"41","author":"Keller K","year":"2020","unstructured":"Keller K, Hobohm L, Ebner M Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in germany. Eur. Heart J. 41(4), 522\u2013529 (2020).","journal-title":"Eur. Heart J."},{"key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan F","year":"2019","unstructured":"Khan F, Rahman A, Carrier M Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 366, l4363 (2019).","journal-title":"BMJ"},{"issue":"4","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides SV","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 41(4), 543\u2013603 (2020).","journal-title":"Eur. Heart J."},{"issue":"19","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel TL","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 4(19), 4693\u20134738 (2020).","journal-title":"Blood Adv."},{"issue":"6","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the Chest Guideline and Expert Panel Report","volume":"160","author":"Stevens SM","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB Antithrombotic therapy for VTE disease: second update of the Chest Guideline and Expert Panel Report. Chest 160(6), e545\u2013e608 (2021).","journal-title":"Chest"},{"issue":"1","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice \u2013 European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos SK","year":"2021","unstructured":"Kakkos SK, Gohel M, Baekgaard N Editor's choice \u2013 European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur. J. Vasc. Endovasc. Surg. 61(1), 9\u201382 (2021).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"8","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/a-1731-3922","article-title":"Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a nationwide comparative cohort study in France","volume":"122","author":"Bertoletti L","year":"2022","unstructured":"Bertoletti L, Gusto G, Khachatryan A Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a nationwide comparative cohort study in France. Thromb. Haemost. 122(8), 1384\u20131396 (2022).","journal-title":"Thromb. Haemost."},{"issue":"11","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1055\/s-0038-1673689","article-title":"Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice","volume":"118","author":"Weycker D","year":"2018","unstructured":"Weycker D, Li X, Wygant GD Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thromb. Haemost. 118(11), 1951\u20131961 (2018).","journal-title":"Thromb. Haemost."},{"issue":"9","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli G","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369(9), 799\u2013808 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham A","year":"2011","unstructured":"Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol. Drug Saf. 20(6), 560\u2013566 (2011).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"Halvorsen S","year":"2017","unstructured":"Halvorsen S, Ghanima W, Fride Tvete I A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur. Heart J. Cardiovasc. Pharmacother. 3(1), 28\u201336 (2017).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson Comorbidity Index conditions in the population-based Danish National Registry of Patients","volume":"11","author":"Thygesen SK","year":"2011","unstructured":"Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson Comorbidity Index conditions in the population-based Danish National Registry of Patients. BMC Med. Res. Methodol. 11, 83 (2011).","journal-title":"BMC Med. Res. Methodol."},{"issue":"6","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson Comorbidity Index and Score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan H","year":"2011","unstructured":"Quan H, Li B, Couris CM Updating and validating the Charlson Comorbidity Index and Score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173(6), 676\u2013682 (2011).","journal-title":"Am. J. Epidemiol."},{"issue":"28","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin PC","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661\u20133679 (2015).","journal-title":"Stat. Med."},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0013"},{"key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic i(2) can be biased in small meta-analyses","volume":"15","author":"von Hippel PT","year":"2015","unstructured":"von Hippel PT. The heterogeneity statistic i(2) can be biased in small meta-analyses. BMC Med. Res. Methodol. 15, 35 (2015).","journal-title":"BMC Med. Res. Methodol."},{"issue":"6","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/joim.13712","article-title":"Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-a nationwide register-based study","volume":"294","author":"Glise Sandblad K","year":"2023","unstructured":"Glise Sandblad K, Schulman S, Rosengren A, Sorbo J, Philipson J, Hansson PO. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-a nationwide register-based study. J. Intern. Med. 294(6), 743\u2013760 (2023).","journal-title":"J. Intern. Med."},{"issue":"11","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1007\/s12325-021-01918-0","article-title":"Effectiveness and safety of apixaban versus warfarin among older patients with venous thromboembolism with different demographics and socioeconomic status","volume":"38","author":"Cohen AT","year":"2021","unstructured":"Cohen AT, Sah J, Dhamane AD Effectiveness and safety of apixaban versus warfarin among older patients with venous thromboembolism with different demographics and socioeconomic status. Adv. Ther. 38(11), 5519\u20135533 (2021).","journal-title":"Adv. Ther."},{"key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish National Inpatient Register","volume":"11","author":"Ludvigsson JF","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A External review and validation of the Swedish National Inpatient Register. BMC Public Health 11, 450 (2011).","journal-title":"BMC Public Health"},{"issue":"6","key":"e_1_3_7_27_2","first-page":"1131","article-title":"Usefulness of health registers for detection of bleeding events in outcome studies","volume":"116","author":"Friberg L","year":"2016","unstructured":"Friberg L, Skeppholm M. Usefulness of health registers for detection of bleeding events in outcome studies. Thromb. Haemost. 116(6), 1131\u20131139 (2016).","journal-title":"Thromb. Haemost."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:14:27Z","timestamp":1761905667000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.57264\/cer-2024-0207"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0207","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"e240207"}}